Maze raises $150M at premium; Phase 1 MZE782 data positive, Phase 2 in 2026

Maze Therapeutics, Inc.

Oversubscribed private placement of $150M gross proceeds at $16.25/share (premium to last close), closed Sept 12.
Issued 4M shares and 5.23M pre-funded warrants; investors include Frazier, Deep Track, Janus Henderson, others.
Phase 1 MZE782 in 112 healthy volunteers: 42-fold urinary Phe excretion, no SAEs, well tolerated.
Dose-dependent eGFR dip similar to SGLT2 inhibitors observed; plans for Phase 2 in PKU and CKD in 2026.
Proceeds to advance MZE829 in APOL1 kidney disease, MZE782 Phase 2, Compass platform, and working capital.

item 1.01item 3.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.